In its third major acquisition in the past six weeks, Gilead is buying a company that will add NaPi2b- and 5T4-targeting agents to its portfolio.

The firm submitted data from the ALKOVE-1 trial, in which neladalkib shrunk tumors in 31 percent of patients and showed promising activity against CNS lesions.

The trial is evaluating how the disclosure of polygenic risk scores for cardiovascular disease affects patients' outcomes.

Preclinical testing has suggested that AIR-001 increases functional AAT protein levels and could address the lung and liver manifestations of the disease.

A study found that in about 10 percent of patients, WGS picked up on clinically actionable information other panels missed.

The firm is clinically testing the dual inhibitor in breast, prostate, colorectal, and lung cancer patients, as Pfizer is also exploring a similar dual-target strategy.

The firm will use the funds from Oberland Capital for pre-launch activities for its gene therapies for Leber congenital amaurosis type 5 and Best disease.

Transgene has licensed the use of NEC's neoantigen prediction platform to support further development of the cancer vaccine TG4050.

The single-site, first-in-human Phase I trial will assess whether the therapy can kill cancer cells in patients who have become resistant to Venclexta.

The firm wants to obtain feedback from the agency on its proposed application for its autologous cell therapy for ischemic heart failure.

Ahead of the full data release and FDA regulatory decision, doctors and researchers parse the limitations of clinical trials ...

H-funded project will build a decision-making tool to help drugmakers and regulators predict treatments likely to work best ...